MYC and familial pancreatic carcinoma: In cancer research, ADAR1 has been implicated in the stabilization of the oncogene c-Myc via the AKT signaling pathway, a mechanism that fosters drug resistance in pancreatic cancer cells, specifically against BET inhibitors [29].